miércoles, 29 de noviembre de 2023

Drug Trial Snapshots: AMVUTTRA (vutrisiran)

AMVUTTRA is a drug for the treatment of nerve damage in adult patients with hereditary transthyretin-mediated amyloidosis. Transthyretin-mediated amyloidosis is the buildup of abnormal deposits of a substance called amyloid in the body's organs and tissues. Amyloid disrupts the function of organs and tissues. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshots-amvuttra

No hay comentarios: